Arcutis Biotherapeutics Inc (ARQT) Stock Price, Quote & News

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 418 5006

Website: www.arcutis.com

Address:

3027 Townsgate Road, Suite 300, Westlake Village, United States

khanso Aug. 29 at 11:06 PM

$ARQT in the interest of full disclosure I have 3000 shares as my core position.…nothing too big! I play around with 1k extra if it’s free and price dips over 5% for no reason! What are you guys holding? Just curious!

0 · Reply

liadanielle Aug. 29 at 4:25 PM

$ARQT Don’t sell, this is a winner! These manipulative pricks can’t scare us away!!

1 · Reply

Franciscomaligno Aug. 29 at 3:41 PM

$ARQT i'm not agree , remember that another pdufa is predicted for midle october.

0 · Reply

khanso Aug. 29 at 2:39 PM

$ARQT Holding on to core position. Waiting for these fuckers to bring it down to double up. Although its very hard to resist buying right now but these bastards can lower it even more. Waiting patiently. 😳

0 · Reply

liadanielle Aug. 28 at 3:29 PM

$ARQT whoever it is they’re bringing the stock shares down purposely to get in cheaper because good news is coming September 30. It’s above my pay grade to know who is doing this.

0 · Reply

AdiDasRom Aug. 28 at 2:42 PM

$ARQT

0 · Reply

zawojak Aug. 28 at 2:01 PM

$ARQT Low $14's and I double my position

0 · Reply

TheGunnerAB Aug. 27 at 9:34 PM

$ARQT they are participating in three investor conferences the next two weeks. I'm expecting a big move upwards.

1 · Reply

liadanielle Aug. 27 at 7:53 PM

$ARQT Recouping starts tomorrow!!

0 · Reply

zawojak Aug. 27 at 1:16 PM

$ARQT Dead money until November ER. Same scenario every time.

0 · Reply

Arcutis: ZORYVE's Multi-Indication Momentum And Margin Expansion Justify A Bullish Re-Rate

Aug 19, 2025, 4:00 PM EDT - 12 days ago

Arcutis to Present at Upcoming Investor Conferences

Aug 8, 2025, 4:00 PM EDT - 23 days ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 7, 2025, 2:53 AM EDT - 24 days ago

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:00 PM EDT - 25 days ago

Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 1, 2025, 3:54 PM EDT - 4 weeks ago

Arcutis: Leveraging Zoryve's Success While Positioning For Pipeline Expansion

Jul 23, 2025, 4:00 PM EDT - 5 weeks ago

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

Jun 27, 2025, 11:25 PM EDT - 2 months ago

Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction

Jun 26, 2025, 8:00 AM EDT - 2 months ago

Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

Jun 25, 2025, 4:43 AM EDT - 2 months ago

Arcutis Biotherapeutics: Another Approval Under Their Belt

Jun 12, 2025, 11:57 PM EDT - 2 months ago

Arcutis: Out Of The Woods, Ready For Commercialization

Jun 10, 2025, 8:00 AM EDT - 2 months ago

Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

Jun 6, 2025, 8:00 AM EDT - 3 months ago

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

Jun 5, 2025, 1:07 AM EDT - 3 months ago

Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside

May 29, 2025, 4:00 PM EDT - 3 months ago

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

May 22, 2025, 2:12 PM EDT - 3 months ago

Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

May 15, 2025, 9:29 AM EDT - 3 months ago

New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice

May 7, 2025, 11:18 AM EDT - 4 months ago

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

May 6, 2025, 11:00 PM EDT - 4 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:00 PM EDT - 4 months ago

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

Apr 19, 2025, 1:41 AM EDT - 4 months ago

Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets

Apr 17, 2025, 8:00 AM EDT - 4 months ago

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

Apr 10, 2025, 4:30 PM EDT - 5 months ago

Arcutis Announces Chief Financial Officer Transition

Apr 2, 2025, 1:16 PM EDT - 5 months ago

Arcutis and Padagis Agree to Stay Patent Lawsuit

Mar 27, 2025, 8:00 AM EDT - 5 months ago

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 8:16 AM EDT - 5 months ago

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

TNXP

Mar 7, 2025, 8:00 AM EST - 6 months ago

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

Feb 28, 2025, 9:00 AM EST - 6 months ago

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

Feb 27, 2025, 6:17 AM EST - 6 months ago

Arcutis: ZORYVE Net Product Revenue Growth Isn't The Only Opportunity On Deck

Feb 26, 2025, 2:28 PM EST - 6 months ago

Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations

Feb 26, 2025, 8:00 AM EST - 6 months ago

U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Feb 25, 2025, 10:53 PM EST - 6 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 4:00 PM EST - 6 months ago

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:00 AM EST - 6 months ago

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology

Feb 18, 2025, 4:35 PM EST - 6 months ago

Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

Feb 4, 2025, 9:15 AM EST - 7 months ago

Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"

Jan 12, 2025, 8:30 AM EST - 8 months ago

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

Nov 15, 2024, 8:30 AM EST - 10 months ago

Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?

Nov 7, 2024, 2:24 AM EST - 10 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:00 PM EST - 10 months ago

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

Oct 23, 2024, 4:00 PM EDT - 11 months ago

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

Oct 22, 2024, 7:36 AM EDT - 11 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4

OGN TMDX

Oct 18, 2024, 8:20 AM EDT - 11 months ago

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Sep 25, 2024, 1:00 AM EDT - 1 year ago

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

Sep 24, 2024, 8:00 AM EDT - 1 year ago

FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Aug 22, 2024, 5:13 PM EDT - 1 year ago

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Aug 22, 2024, 8:00 AM EDT - 1 year ago

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 15, 2024, 12:43 AM EDT - 1 year ago

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 9:00 PM EDT - 1 year ago

CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 4:00 PM EDT - 1 year ago

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

khanso Aug. 29 at 11:06 PM

0 · Reply

liadanielle Aug. 29 at 4:25 PM

$ARQT Don’t sell, this is a winner! These manipulative pricks can’t scare us away!!

1 · Reply

Franciscomaligno Aug. 29 at 3:41 PM

$ARQT i'm not agree , remember that another pdufa is predicted for midle october.

0 · Reply

khanso Aug. 29 at 2:39 PM

0 · Reply

liadanielle Aug. 28 at 3:29 PM

$ARQT whoever it is they’re bringing the stock shares down purposely to get in cheaper because good news is coming September 30. It’s above my pay grade to know who is doing this.

0 · Reply

AdiDasRom Aug. 28 at 2:42 PM

$ARQT

0 · Reply

zawojak Aug. 28 at 2:01 PM

$ARQT Low $14's and I double my position

0 · Reply

TheGunnerAB Aug. 27 at 9:34 PM

$ARQT they are participating in three investor conferences the next two weeks. I'm expecting a big move upwards.

1 · Reply

liadanielle Aug. 27 at 7:53 PM

$ARQT Recouping starts tomorrow!!

0 · Reply

zawojak Aug. 27 at 1:16 PM

$ARQT Dead money until November ER. Same scenario every time.

0 · Reply

liadanielle Aug. 26 at 5:20 PM

$ARQT

0 · Reply

liadanielle Aug. 25 at 7:59 PM

$ARQT One of my top 5 for the end of the year: https://youtu.be/AWl1dHkqXHs

0 · Reply

liadanielle Aug. 25 at 5:21 PM

$ARQT October 13 is a big day for us!! 20+

1 · Reply

Dilly_Poppins Aug. 25 at 3:43 PM

$ARQT potential bull flag on daily

0 · Reply

BreakoutForge Aug. 23 at 6:00 AM

$ARQT Arcutis Biotherapeutics is a dermatology company with approved products facing launch challenges

2 · Reply

TheBiotechInvestor_ Aug. 22 at 9:36 PM

$ARQT One of my top 5 for the end of the year: https://youtu.be/AWl1dHkqXHs

0 · Reply

Bornjever Aug. 22 at 2:26 PM

$ARQT next earn just came out and 1105 is date as earnings will cause this to jump to 20-25 per share and we can see folks want our shares at 16 or less??? I can wait till then but if buyout comes at 25 per share and we avoid the wait I am ok with that also

1 · Reply

zawojak Aug. 22 at 9:44 AM

$ARQT Insider sale today 😬

0 · Reply

WycklyTrader Aug. 22 at 1:54 AM

$PGEN Precigen 3-yr consolidation breakout on FDA approval, potential target $10. $AIRS Airsculpt 3-yr consolidation + high short interest = potential squeeze target $18. $ARQT Arcutis weekly golden cross consolidation anticipating 52 week high breakout, potential target $26. $QQQ $GME 'S...

0 · Reply

Dilly_Poppins Aug. 21 at 2:37 PM

$ARQT Watching $15.40 level to act as long term support, if we hold this. $17.70 is long term resistance and also middle of the channel we have been in since the 2024 breakout (see exhibit A) . Above $17.70 and I think we have a good chance to hit $21 before reverting to the mean. Side note: currently at the 61.8% Fib. September is predominately a down month for this stock while market in general can be choppy, we have a rate cut decision on Sep 17th and rates affect have a big effect. That said we have grounded out on the bottom of the channel about 6 distinct times since April so maybe this time it’s different but bracing for volatility over next 4-6 weeks 🌬️ Exhibit A:

0 · Reply

AdiDasRom Aug. 21 at 1:49 PM

$ARQT

0 · Reply

Chasetae Aug. 20 at 1:54 PM

$ARQT shorts have better places to play than here.

0 · Reply

Market Cap	1.86B
Revenue (ttm)	196.54M
Net Income (ttm)	-140.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-71.25%
Debt to Equity Ratio	0.78

Volume	1,185,300
Avg Vol	1,704,934
Day's Range	N/A - N/A
Shares Out	119.91M
Stochastic %K	25%
Beta	1.84
Analysts	Strong Sell
Price Target	$22.62